Académique Documents
Professionnel Documents
Culture Documents
40,953.37
279,551.86
320,505.23
40,950.61
279,509.56
320,460.17
69,743.33
31.84
1,527.02
704.11
72,006.30
67,978.23
0
7,641.56
466.12
76,085.91
30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41
42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23
11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88
8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20
30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41
0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23
148,966.83
4,115.07
357,383.04
40,953.37
279,551.86
320,505.23
9.14%
62.42%
71.57%
69,743.33
31.84
1,527.02
704.11
72,006.30
15.57%
0.01%
0.34%
0.16%
16.08%
30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41
6.71%
1.06%
4.41%
0.17%
12.35%
100%
11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88
2.56%
0.07%
1.63%
4.25%
46.95%
18.73%
3.89%
73.83%
0.00%
6.77%
0.11%
2.08%
2.42%
14.52%
0.27%
26.17%
100.00%
30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41
40,950.61
279,509.56
320,460.17
67,978.23
0
7,641.56
466.12
76,085.91
42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23
8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20
0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23
9.11%
62.15%
71.25%
0.00%
15.11%
0.00%
1.70%
0.10%
16.92%
0.00%
9.40%
1.03%
1.31%
0.09%
11.83%
100.00%
1.85%
0.03%
1.08%
2.96%
51.36%
11.19%
0.37%
65.89%
0.00%
0.00%
0.09%
1.39%
0.33%
30.96%
1.34%
34.11%
100.00%
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013
March 31, 2013
in Lacs
INCOME
Revenue from operations
Other income
Exceptional items
Total revenue
EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Total expenses
Earnings before interest, tax, depreciation and amortization (EBITDA)
Finance costs
Profit before tax, depreciation and amortization
Depreciation and amortization expense
Profit before tax
Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses
Profit for the year
Earnings per share [Nominal value of shares ` 10/- each (Previous year ` 10/- each)
Basic
Diluted
35,297.21
19,056.93
0
54,354.14
10,187.06
-51.39
10,133.14
15,144.46
35,413.27
18,940.87
13,386.47
5,554.40
2,346.83
3,207.57
1,450.85
0
31.84
1,482.69
1,724.88
0.43
0.43
7,951.71
-95.56
7,073.50
12,721.55
27,651.20
31,643.38
10,293.40
21,349.98
1,211.44
20,138.54
4,030.45
-4,030.45
0
0.00
20,138.54
4.97
4.97
1894087%
172488%
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013
INCOME
Revenue from operations
Total revenue
EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Depreciation and amortization expense
Total expenses
Earnings before interest, tax, depreciation and amortization (EBITDA)
Profit before tax
Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses
Current Year Income Tax
Tax on Other Income
Tax on Finance costs
Tax on Exceptional items
Net Tax
Net Operating Profit after tax (NOPAT)
NOPAT
Other income (Net of Tax)
Finance costs (Net of Tax)
Profit after tax before exceptional items
Exceptional items (Net of Tax)
28,127.97
28,127.97
10,187.06
-51.39
10,133.14
15,144.46
2,346.83
37,760.10
7,951.71
-95.56
7,073.50
12,721.55
1,211.44
28,862.64
-2,462.89
0.00
-2,462.89
-734.67
0.00
-734.67
1,450.85
0
31.84
1,482.69
4,030.45
-4,030.45
0
0.00
1,482.69
6,183.02
4,343.24
0.00
-357.09
0.00
4,121.89
3,339.69
5,990.12
-6,772.31
-2,105.80
6,037.64
-2,105.80
12,873.91
9,043.23
1,724.88
6,037.64
8,582.35
6,953.71
7,666.29
0.00
1,724.88
12,472.25
20,138.54
19,056.93
13,386.47
0
12,704.24
10,293.40
18,462.37
Tax percentage
32.445
448,787.82
235,798.17
212,989.65
403,566.14
192,045.04
211,521.10
0.38%
-0.99%
1.90%
2.85%
7.87%
16.57%
6.97%
13.30%
40,953.37
279,551.86
320,505.23
40,950.61
279,509.56
320,460.17
69,743.33
31.84
1,527.02
704.11
72,006.30
67,978.23
0
7,641.56
466.12
76,085.91
30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41
42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23
11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88
8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20
30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41
0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23
Change
Amount
2.76
42.30
45.06
0%
0%
0%
1,765.10
31.84
-6,114.54
237.99
-4,079.61
3%
-80%
51%
-5%
-12,209.56
96.70
13,876.10
348.49
2,111.73
-1,922.82
-29%
2%
236%
84%
4%
0%
3,132.80
173.92
2,429.14
5,735.86
-20,739.71
33,543.31
15,763.22
34,302.68
38%
133%
50%
43%
-9%
67%
947%
12%
30,319.71
59.57
3,055.53
9,371.46
-74,218.55
-4,813.22
-36,225.50
-1,922.82
14%
49%
630%
-53%
-80%
-24%
0%
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013
March 31, 2013
in Lacs
INCOME
Revenue from operations
Other income
Exceptional items
Total revenue
35,297.21
19,056.93
0
54,354.14
EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Total expenses
10,187.06
51.39
10,133.14
15,144.46
35,413.27
18,940.87
13,386.47
5,554.40
2,346.83
3,207.57
Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses
1,450.85
0
31.84
1,482.69
1,724.88
Earnings per share [Nominal value of shares ` 10/- each (Previous year ` 10/- each)
Basic
Diluted
0.43
0.43
7,951.71
95.56
7,073.50
12,721.55
27,651.20
25%
50%
-100%
-8%
2,235.35
-44.17
3,059.64
2,422.91
7,762.07
28%
-46%
43%
19%
28%
31,643.38 -12,702.51
10,293.40 3,093.07
21,349.98 -15,795.58
-40%
30%
-74%
1,211.44 1,135.39
20,138.54 -16,930.97
94%
-84%
4,030.45
4,030.45
0
0
-2,579.60
-4,030.45
31.84
1,482.69
-64%
-100%
20,138.54 -18,413.66
-91%
4.97
4.97
-4.54
-4.54
-91%
-91%
Profitability Ratios
Amounts in Rs. Lacs
Ratio
Formula
A Return on Equity
2012-2013
1,724.88
320,505.23
0.54%
1,724.88
35,297.21
4.89%
NOPAT
Sales
(2,105.80)
35,297.21
-5.97%
D Return on Assets
Profit margin
Sales
Total Assets
1,724.88
448,787.82
0.38%
1,724.88
35,297.21
4.89%
35,297.21
448,787.82
7.87%
1,724.88
0.54%
Equity
320,505.23
1,724.88
35,297.21
4.89%
Sales
Total Assets
35,297.21
448,787.82
7.87%
Leverage
Total Assets
Total Equity
448,787.82
320,505.23
140.03%
Profit margin
Liquidity Ratios
Amounts in Rs. Lacs
Ratio
Formula
2012-2013
2011-12
A Current Ratio
117,201.53
55,314.88
2.12 : 1
153,427.03
53,203.15
2.884 : 1
116,716.67
55,314.88
2.11 : 1
153,001.74
53,203.15
2.876 : 1
Sales
Inventory
35,297.21
484.86
28,127.97
425.29
66.14 Times
No of days in a year
Inventory Turnover Ratio
Sales Turnover
Sundry Debtors
No of days in a year
Debtors Turnover Ratio
365
72.80
35,297.21
9,305.03
365
3.79
72.80 Times
5.01 Days
3.79 Times
96.22 Days
365
66.14
28,127.97
6,249.50
365
4.50
5.52 Days
4.50 Times
81.10 Days
Solvency Ratios
Amounts in Rs. Lacs
Ratio
Formula
2011-12
2011-12
Total Borrowings
Sharholders' Funds
there are no loans taken by the company. Hence this ratio is not applicable to Fortis Healthcare
Total Liabilities.
Sharholders' Funds
447,826.41
320,505.23
1.40 : 1
449,749.23
320,460.17
1.40 : 1
C Leverage
Total Assets
Total Equity
447,826.41
320,505.23
1.40 : 1
449,749.23
320,460.17
1.40 : 1
PBIT(from pg.29)
Interest Expense
(2,462.89)
13,386.47
(0.18) times
(734.67)
10,293.40
(0.07) times
ortis Healthcare
Formula
2011-12
2010-11
(a) Basic
(b) Diluted
0.43
0.43
4.97
4.97
Market Price
Earnings Per Share
466.1
0.43
0
466.1
1,083.95
0.00%
409.9
4.97
82.47
0
409.9
0.00%